{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:12:00Z","timestamp":1792552320225,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Covalent inhibitors of Bruton tyrosine kinase (BTK) have transformed the therapy of chronic lymphocytic leukemia (CLL), but continuous therapy has been complicated by the development of resistance. The most common resistance mechanism in patients whose disease progresses on covalent BTK inhibitors (BTKis) is a mutation in the BTK 481 cysteine residue to which the inhibitors bind covalently. Pirtobrutinib is a highly selective, noncovalent BTKi with substantial clinical activity in patients whose disease has progressed on covalent BTKi, regardless of BTK mutation status. Using in\u00a0vitro ibrutinib-resistant models and cells from patients with CLL, we show that pirtobrutinib potently inhibits BTK-mediated functions including B-cell receptor (BCR) signaling, cell viability, and CCL3\/CCL4 chemokine production in both BTK wild-type and C481S mutant CLL cells. We demonstrate that primary CLL cells from responding patients on the pirtobrutinib trial show reduced BCR signaling, cell survival, and CCL3\/CCL4 chemokine secretion. At time of progression, these primary CLL cells show increasing resistance to pirtobrutinib in signaling inhibition, cell viability, and cytokine production. We employed longitudinal whole-exome sequencing on 2 patients whose disease progressed on pirtobrutinib and identified selection of alternative-site BTK mutations, providing clinical evidence that secondary BTK mutations lead to resistance to noncovalent BTKis.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008447","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T11:07:14Z","timestamp":1666782434000},"page":"1929-1943","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":88,"title":["Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance"],"prefix":"10.1182","volume":"7","author":[{"given":"Aishath","family":"Naeem","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"2Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3226-7642","authenticated-orcid":false,"given":"Filippo","family":"Utro","sequence":"additional","affiliation":[{"name":"3IBM Research, Yorktown Heights, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[{"name":"4Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86, Huddinge, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Cha","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauno","family":"Vihinen","sequence":"additional","affiliation":[{"name":"5Department of Experimental Medical Science, Lund University, SE-221 84, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Martindale","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6276-635X","authenticated-orcid":false,"given":"Yinglu","family":"Zhou","sequence":"additional","affiliation":[{"name":"6Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ren","sequence":"additional","affiliation":[{"name":"6Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-6507","authenticated-orcid":false,"given":"Svitlana","family":"Tyekucheva","sequence":"additional","affiliation":[{"name":"6Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8699-2439","authenticated-orcid":false,"given":"Annette S.","family":"Kim","sequence":"additional","affiliation":[{"name":"7Department of Pathology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey M.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6630-7935","authenticated-orcid":false,"given":"Gordon","family":"Saksena","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1567-9090","authenticated-orcid":false,"given":"Kahn","family":"Rhrissorrakrai","sequence":"additional","affiliation":[{"name":"3IBM Research, Yorktown Heights, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaya","family":"Levovitz","sequence":"additional","affiliation":[{"name":"3IBM Research, Yorktown Heights, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Danysh","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Slowik","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel A.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"8Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Lederer","sequence":"additional","affiliation":[{"name":"9Department of Surgery, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8327-846X","authenticated-orcid":false,"given":"Rula","family":"Zain","sequence":"additional","affiliation":[{"name":"4Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86, Huddinge, Sweden"},{"name":"10Centre for Rare Diseases, Department of Clinical Genetics, Karolinska University Hospital, SE-171 76, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1907-3392","authenticated-orcid":false,"given":"C. I. Edvard","family":"Smith","sequence":"additional","affiliation":[{"name":"4Department of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86, Huddinge, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignaty","family":"Leshchiner","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmi","family":"Parida","sequence":"additional","affiliation":[{"name":"3IBM Research, Yorktown Heights, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad","family":"Getz","sequence":"additional","affiliation":[{"name":"2Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"11Department of Pathology, Harvard Medical School, Boston, MA"},{"name":"12Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"2Cancer Program, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA"},{"name":"8Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"issue":"3","key":"2023050915233517100_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2018.1435268","article-title":"Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?","volume":"11","author":"Lampson","year":"2018","journal-title":"Expet Rev Hematol"},{"issue":"13","key":"2023050915233517100_bib2","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2023050915233517100_bib3","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2023050915233517100_bib4","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2023050915233517100_bib5","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/leu.2017.110","article-title":"PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment","volume":"31","author":"Jones","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2023050915233517100_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023050915233517100_bib7","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1021\/acschembio.6b00480","article-title":"Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations","volume":"11","author":"Johnson","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"7","key":"2023050915233517100_bib8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.2019000854","article-title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study","volume":"134","author":"Quinquenel","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2023050915233517100_bib9","article-title":"Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"10277","key":"2023050915233517100_bib10","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"2023050915233517100_bib11","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1111\/bph.14809","article-title":"A\u00a0non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk(C481S) mutation in B-cell malignancies","volume":"176","author":"Gui","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"4","key":"2023050915233517100_bib12","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.bmc.2014.10.043","article-title":"Discovery of novel Bruton\u2019s tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold","volume":"23","author":"Zhao","year":"2015","journal-title":"Bioorg Med Chem"},{"issue":"10","key":"2023050915233517100_bib13","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov"},{"issue":"10","key":"2023050915233517100_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2017-10-809020","article-title":"Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL","volume":"132","author":"Reiff","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2023050915233517100_bib15","article-title":"Preliminary efficacy and safety of MK-1026, a non-covalent inhibitor of wild-type and C481S mutated Bruton tyrosine kinase, in B-cell malignancies: a phase 2 dose expansion study","volume":"138","author":"Woyach","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2023050915233517100_bib16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023050915233517100_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1084\/jem.184.1.31","article-title":"A\u00a0role for Bruton\u2019s tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2","volume":"184","author":"Takata","year":"1996","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"2023050915233517100_bib18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbrc.2008.10.040","article-title":"Expression profiling of chicken DT40 lymphoma cells indicates clonal selection of knockout and gene reconstituted cells","volume":"377","author":"Nawaz","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"2023050915233517100_bib19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","article-title":"BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib","volume":"35","author":"Estupinan","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2023050915233517100_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/leu.2016.153","article-title":"Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant","volume":"31","author":"Hamasy","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2023050915233517100_bib21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nbt.2203","article-title":"Absolute quantification of somatic DNA alterations in human cancer","volume":"30","author":"Carter","year":"2012","journal-title":"Nat Biotechnol"},{"key":"2023050915233517100_bib22","doi-asserted-by":"crossref","first-page":"8866","DOI":"10.1038\/ncomms9866","article-title":"Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution","volume":"6","author":"Kasar","year":"2015","journal-title":"Nat Commun"},{"key":"2023050915233517100_bib23","article-title":"Comprehensive analysis of tumour initiation, spatial and temporal progression under multiple lines of treatment","author":"Leshchiner","year":"16  2019","journal-title":"bioRxiv"},{"issue":"suppl 5","key":"2023050915233517100_bib24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s12864-021-07660-9","article-title":"A common methodological phylogenomics framework for intra-patient heteroplasmies to infer SARS-CoV-2 sublineages and tumor clones","volume":"22","author":"Utro","year":"2021","journal-title":"BMC Genom"},{"issue":"29","key":"2023050915233517100_bib25","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl 1","key":"2023050915233517100_bib26","article-title":"Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"13","key":"2023050915233517100_bib27","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2023050915233517100_bib28","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in\u00a0vitro and in\u00a0vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2023050915233517100_bib29","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2021.280061","article-title":"Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton\u2019s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies","volume":"107","author":"Allan","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"2023050915233517100_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat Biotechnol"},{"key":"2023050915233517100_bib31","doi-asserted-by":"crossref","first-page":"694853","DOI":"10.3389\/fimmu.2021.694853","article-title":"Structure-function relationships of covalent and non-covalent BTK inhibitors","volume":"12","author":"Zain","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"2023050915233517100_bib32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-022-00675-9","article-title":"Pirtobrutinib inhibits wild-type and mutant Bruton\u2019s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia","volume":"12","author":"Aslan","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"2023050915233517100_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"20","key":"2023050915233517100_bib34","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2023050915233517100_bib35","article-title":"BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib","volume":"134","author":"Blombery","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2023050915233517100_bib36","article-title":"Loxo-305, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations","volume":"134","author":"Gomez","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2023050915233517100_bib37","article-title":"LOXO-305: targeting C481S Bruton tyrosine kinase in patients with ibrutinib-resistant CLL","volume":"134","author":"Naeem","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2023050915233517100_bib38","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.20.00979","article-title":"Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model","volume":"39","author":"Ahn","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"2023050915233517100_bib39","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1182\/blood-2016-01-695098","article-title":"HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib","volume":"127","author":"Yang","year":"2016","journal-title":"Blood"},{"issue":"736","key":"2023050915233517100_bib40","doi-asserted-by":"crossref","first-page":"eabg5216","DOI":"10.1126\/scisignal.abg5216","article-title":"Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK","volume":"15","author":"Dhami","year":"2022","journal-title":"Sci Signal"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/9\/1929\/2048984\/blooda_adv-2022-008447-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/9\/1929\/2048984\/blooda_adv-2022-008447-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T23:57:53Z","timestamp":1683676673000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/9\/1929\/486896\/Pirtobrutinib-targets-BTK-C481S-in-ibrutinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,5,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008447","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]}}}